In-beam internal conversion electron spectroscopy with the SPICE detector

The SPectrometer for Internal Conversion Electrons (SPICE) has been commissioned for use in conjunction with the TIGRESS $\gamma$-ray spectrometer at TRIUMF's ISAC-II facility. SPICE features a permanent rare-earth magnetic lens to collect and direct internal conversion electrons emitted from nuclear reactions to a thick, highly segmented, lithium-drifted silicon detector. This arrangement, combined with TIGRESS, enables in-beam $\gamma$-ray and internal conversion electron spectroscopy to be performed with stable and radioactive ion beams. Technical aspects of the device, capabilities, and initial performance are presented

Half-lives of neutron-rich Cd 128-130

R. Dunlop et al. ; 6 págs.; 7 figs.; 1 tab. ; Rapid CommunicationsThe β-decay half-lives of Cd128-130 have been measured with the newly commissioned GRIFFIN γ-ray spectrometer at the TRIUMF-ISAC facility. The time structures of the most intense γ rays emitted following the β decay were used to determine the half-lives of Cd128 and Cd130 to be T1/2=246.2(21) ms and T1/2=126(4) ms, respectively. The half-lives of the 3/2+ and 11/2- states of Cd129 were measured to be T1/2(3/2+)=157(8) ms and T1/2(11/2-)=147(3) ms. The half-lives of the Cd isotopes around the N=82 shell closure are an important ingredient in astrophysical simulations to derive the magnitude of the second r-process abundance peak in the A∼130 region. Our new results are compared with recent literature values and theoretical calculations. ©2016 American Physical SocietyThis work has been partially supported by the Natural Sciences and Engineering Research Council of Canada (NSERC) and the Canada Research Chairs Program. I.D. and R.C.-F. are supported by NSERC Discovery Grants SAPIN-2014-00028 and RGPAS 462257-2014. A.J. acknowledges financial support by the Spanish Ministerio de Ciencia e Innovación under contract FPA2011-29854-C04 and the Spanish Ministerio de Economía y Competitividad under contract FPA2014- 57196-C5-4-P. S.L.T acknowledges financial support from the U.S. National Science Foundation under contract NSF- 14-01574. E.P.-R. acknowledges financial support from the DGAPA-UNAM under the PASPA program. The GRIFFIN spectrometer was funded by the Canada Foundation for Innovation, TRIUMF, and the University of Guelph. TRIUMF receives federal funding via a contribution agreement with the National Research Council of Canada.Peer Reviewe

Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma

Malignant pleural mesothelioma is a notoriously chemoresistant tumour. However, a recent single institution study showed an impressive activity of gemcitabine and cisplatin. Our aim is to investigate the efficacy and toxicity of a gemcitabine and cisplatin combination in selected and chemo-naive patients with histologically proven malignant pleural mesothelioma. Method: Gemcitabine 1250 mg m−2 was administered on day 1 and day 8 and cisplatin 80 mg m−2 was administered on day 1 in a 3-week cycle with a maximum of six cycles. Response and toxicity evaluations were performed according to WHO and NCIC-CTC criteria. Pathology and radiology were centrally reviewed. Results show that in 25 evaluable patients, four PR were observed (ORR 16%, 95% CI 1–31%). Responses of seven patients were unevaluable. No unexpected toxicity occurred. Time to progression was 6 months (5–7 months) with a median survival from registration of 9.6 months (95% CI 8–12 months). In conclusion this trial excludes with 90% power a response rate of greater than 30% in patients with malignant pleural mesothelioma using a combination of gemcitabine and cisplatin at the proposed dose and schedule

Safety and efficacy of the supreme biodegradable polymer sirolimus-eluting stent in patients with diabetes mellitus

Patients with diabetes mellitus (DM) have worse outcomes following percutaneous coronary intervention than nondiabetic patients. The novel Supreme DES is a biodegradable polymer sirolimus-eluting stent designed to synchronize early drug delivery, limiting the potential for long-term inflammatory response. The purpose of this study was to evaluate the safety and efficacy of the Supreme DES in patients with DM. Methods This is a prespecified analysis of the diabetic subgroup from the PIONEER III randomized (2:1), controlled trial, comparing the Supreme DES with a durable polymer everolimus-eluting stent (DP-EES). The primary safety and efficacy composite endpoint was target lesion failure at 1 year, a composite of cardiac death, target vessel myocardial infarction, or clinically driven target lesion revascularization. Results The PIONEER III trial randomized 1629 patients, of which 494 (30.3%) had DM with 331 (398 lesions) randomly assigned to Supreme DES and 163 (208 lesions) to DP-EES. Among patients with DM, target lesion failure at 1 year was 6.1% (20/331) with Supreme DES vs 3.7% (6/163) with DP-EES (hazard ratio = 1.65; 95% confidence interval = 0.66-4.10, P = .28). The composite of cardiac death or target vessel myocardial infarction was 3.3% (11/331) with Supreme DES and 3.7% (6/163) with DP-EES (hazard ratio = 0.90; 95% confidence interval = 0.33-2.44, P = .83). There were no significant differences in other secondary endpoints. Conclusions This prespecified substudy of the PIONEER III trial demonstrated the relative safety and efficacy of the novel Supreme DES when compared with commercially available DP-EES in diabetics at 1 year. Longer term follow-up will be required to ensure continued safety and efficacy of the Supreme DES

The Potential Involvement of E-cadherin and β-catenins in Meningioma

To investigate the potential involvements of E-cadherin and β-catenin in meningioma.Immunohistochemistry staining was performed on samples from patients with meningioma. The results were graded according to the positive ratio and intensity of tissue immunoreactivity. The expression of E-cadherin and β-catenin in meningioma was analyzed by its relationship with WHO2007 grading, invasion, peritumoral edema and postoperative recurrence.The positive rates of E-cadherin in meningioma WHO I, II, III were 92.69%, 33.33% and 0, respectively, (P<0.05); while the positive rates of β-catenin in meningioma WHO I, II, III were 82.93%, 33.33% and 20.00%, respectively, (P<0.05). The positive rate of E-cadherin in meningioma without invasion (94.12%) was higher than that with invasion (46.67%) (P<0.05). The difference in the positive rate of β-catenin between meningioma without invasion (88.24%) and meningioma with invasion (33.33%, P<0.05) was also statically significant. The positive rates of E-cadherin in meningioma with peritumoral edema 0, 1, 2, 3 were 93.75%, 85.71%, 60.00% and 0 respectively, (P<0.05); the positive rates of β-catenin in meningioma with peritumoral edema 0, 1, 2, 3 were 87.50%, 85.71%, 30.00% and 0 respectively, (P<0.01). The positive rates of E- cadherin in meningioma with postoperative recurrence were 33.33%, and the positive rate with postoperative non-recurrence was 90.00% (P<0.01). The positive rates of β-catenin in meningioma with postoperative recurrence and non-recurrence were 11.11%, 85.00%, respectively (P<0.01).The expression levels of E- cadherin and β-catenin correlated closely to the WHO 2007 grading criteria for meningioma. In atypical or malignant meningioma, the expression levels of E-cadherin and β-catenin were significantly lower. The expression levels of E- cadherin and β-catenin were also closely correlated with the invasion status of meningioma, the size of the peritumoral edema and the recurrent probabilities of the meningioma, all in an inverse correlationship. Taken together, the present study provided novel molecular targets in clinical treatments to meningioma

Decay spectroscopy of Cd-129

Excited states of $^{129}$In populated following the $\beta$-decay of $^{129}$Cd were experimentally studied with the GRIFFIN spectrometer at the ISAC facility of TRIUMF, Canada. A 480-MeV proton beam was impinged on a uranium carbide target and $^{129}$Cd was extracted using the Ion Guide Laser Ion Source (IG-LIS). $\beta$- and $\gamma$-rays following the decay of $^{129}$Cd were detected with the GRIFFIN spectrometer comprising the plastic scintillator SCEPTAR and 16 high-purity germanium (HPGe) clover-type detectors. %, along with the $\beta$-particles were detected with SCEPTAR. From the $\beta$-$\gamma$-$\gamma$ coincidence analysis, 32 new transitions and 7 new excited states were established, expanding the previously known level scheme of $^{129}$In. The $\log ft$ values deduced from the $\beta$-feeding intensities suggest that some of the high-lying states were populated by the $\nu 0 g_{7/2} \rightarrow \pi 0 g_{9/2}$ allowed Gamow-Teller (GT) transition, which indicates that the allowed GT transition is more dominant in the $^{129}$Cd decay than previously reported. Observation of fragmented Gamow-Teller strengths is consistent with theoretical calculations.Comment: 13 pages, 9 figures, to be published in Physical Review